Cartalax
Cartalax
Description
A bioregulator peptide for joint and cartilage health. Supports joint tissue regeneration and reduces age-related cartilage degradation.
Overview
Cartalax is a short bioregulatory compound being explored for relevance to joint health, cartilage maintenance, and age-associated changes in connective tissue, extracellular-matrix balance, and cell-stress responses.
Mechanism of Action
Cartalax (tripeptide AED, alanine-glutamate-aspartate) is described as a tissue-targeted ultrashort peptide that may influence gene expression, cell renewal, and local signaling pathways involved in cartilage structure, matrix proteins, and joint resilience, potentially via direct interactions with chromatin components or DNA.
Benefits
- •Joint health
- •Cartilage support
- •Tissue regeneration
- •Mobility
Reported Side Effects
- •Limited human safety data
- •Possible injection site reactions
Safety Notes
No clinical safety profile exists. Cartalax is not approved for human use; it is used only under institutional oversight in qualified research settings.
Scientific References
Related Bioregulator Peptides
Vesugen
Vesugen
A vascular bioregulator peptide supporting blood vessel health and circulation. Important for cardiovascular longevity.
2 mgLivagen
Livagen
A liver bioregulator peptide supporting hepatic tissue regeneration and function. Essential for metabolic and detoxification health.
2 mgChonluten
Chonluten
A respiratory bioregulator peptide supporting bronchial mucosa and lung function. Part of comprehensive respiratory health protocols.
2 mgPancragen
Pancragen
A pancreatic bioregulator peptide supporting pancreatic tissue health and metabolic function. Important for blood sugar regulation.
2 mg